Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Effects of metreleptin in patients with lipodystrophy with and without baseline concomitant medication use

Open access

Abstract

OBJECTIVE: To evaluate the effects of metreleptin in distinct subgroups of patients with generalized lipodystrophy (GL) and partial lipodystrophy (PL), using multivariate linear regression modeling to account for the role of patients' baseline usage of concomitant glucose and lipid-lowering medications and other covariates on their outcomes. MATERIALS AND METHODS: statistical analysis of two published single-arm, interventional, phase 2 clinical trials at NIH was conducted. Concomitant medication use was assessed for the clinical trial population using prescription fill data, measured at baseline and the post-one year following metreleptin initiation. Pre-specified co-primary efficacy endpoints measured were change from baseline in HbA1c at month 12, and the percent change from baseline in fasting serum triglycerides (TG) at month 12. Descriptive and statistical analyses were conducted for the overall population, the separate populations with GL and PL, and additional PL subgroups defined by baseline metabolic markers of elevated HbA1c and elevated fasting TG. RESULTS: As previously reported, improvement in HbA1c and fasting TG from baseline to 12 months on metreleptin were observed in the overall population (mean change -1.57 percentage points and median change -37.9%, respectively) and subgroups. For both HbA1c and TG, baseline levels were significant predictors of changes after metreleptin. After considering baseline characteristics such as disease type, age, sex, and baseline HbA1c, baseline insulin use was not found to be a significant predictor of HbA1c improvement following metreleptin initiation. Similar results were seen for TG levels, with the use of any lipid-lowering medications at baseline not found to be a significant predictor of reductions in fasting TG levels. CONCLUSIONS: Patients treated with metreleptin experienced statistically significant improvement in metabolic markers of glycemic and hypertriglyceridemic control-e.g. HbA1c and triglyceride levels-across various subgroups after controlling for baseline characteristics and concomitant medication usage.

Overview

Integrity signals

Registry

Crossref · 10.1080/03007995.2021.1976125

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 17 references

Research works printed but not linked: 2

  1. Myalept (metreleptin) for injection for subcutaneous use [prescribing information] Cambridge, MA: Aegerion Pharmaceuticals Inc. 2020. [updated May; cited 2020 July 6]. Available from: http://www.myalept.com/prescribing-information
  2. Alexopoulos EC., 2010, Hippokratia, 14, 23

Cited by

See all 11

Metadata

Authors
Adamski, K., Cook, K., Gupta, D., Morris, E., Tuttle, E., Carr, E., Cremasco, F., Cochran, E., & Brown, R. J.
Affiliations
  • Analysis Group (United States) (US)
  • Amryt Pharmaceuticals DAC, Dublin, Ireland
  • National Institute of Diabetes and Digestive and Kidney Diseases (US)
Corresponding author
Cook, Keziah
Venue
Current Medical Research and Opinion
Published
2021-09-26
Volume
37
Issue
11
Pages
1881-1889
ISSN
  • 0300-7995 (ISSN-L)
  • 1473-4877
OpenAlex
W3198114250
Cited by
11
References
17
Citations by year
2026: 1 · 2025: 1 · 2024: 4 · 2023: 2 · 2022: 3
FWCI
1.18
Type
journal article
Language
en
Open access
Locations
  • Current Medical Research and Opinion (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
Amryt Pharmaceuticals and Aegerion Pharmaceuticals
Topics
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
Keywords
metreleptin, lipodystrophy, generalized lipodystrophy, partial lipodystrophy, HbA1c, glucose-lowering medications, lipid-lowering drugs, insulin use, predictors of treatment response, hypertriglyceridemia, glycemic control
MeSH terms
Blood Glucose, Fasting, Humans, Lipodystrophy, Leptin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of metreleptin in patients with lipodystrophy with and without baseline concomitant medication use. https://app.cochat.ai/papers/10.1080/03007995.2021.1976125
The paper
Adamski, K., Cook, K., Gupta, D., Morris, E., Tuttle, E., Carr, E., Cremasco, F., Cochran, E., & Brown, R. J. (2021). Effects of metreleptin in patients with lipodystrophy with and without baseline concomitant medication use. Current Medical Research and Opinion. https://doi.org/10.1080/03007995.2021.1976125

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.